Gefurulimab  (Synonyms: ALXN-1720)

Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis^[1][2][3].

VH-VH'

Human

C5 (complement 5, C5a anaphylatoxin)

Gefurulimab binds specifically and with high affinity to human and cynomolgus monkey C5 and serum albumin; its affinity for C5 exhibits pH-dependent changes, whereas its affinity for HSA shows little pH dependence, and it can bind hC5 and HSA simultaneously^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

727  [NCBI] & 728  [NCBI]

P01031 & P21730

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

28.17 kDa

2456407-94-4

Liquid

Colorless to light yellow

[Gefurulimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  VH-VH'

• [1]. Sandra Rayego-Mateos, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2022 Dec 5:S0085-2538(22)01017-1.  [Content Brief]

  [2]. Mullin M, et al. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions. MAbs. 2024 Jan-Dec;16(1):2341443.  [Content Brief]

  [3]. Miwa T, et al. Expansion of Anticomplement Therapy Indications from Rare Genetic Disorders to Common Kidney Diseases. Annu Rev Med. 2024 Jan 29;75:189-204.  [Content Brief]

  [4]. Jindal S, et al. Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration. Mol Immunol. 2024;165:29-41.  [Content Brief]